鉴定肺癌患者是否增加感染SARS-CoV-2相关并发症的风险有助于制定个性化治疗方案，以最大程度地发挥抗癌治疗的好处，同时减少COVID-19并发症的可能性。本研究旨在确定预测肺癌患者死亡或严重SARS-CoV-2感染风险的特征。本研究是一项回顾性队列研究，涉及2015年10月1日至2020年12月1日期间诊断为肺癌并于2020年2月2日至12月1日期间被诊断为COVID-19的退伍军人事务管理局患者。严重的SARS-CoV-2感染被定义为在COVID-19诊断后2周内需要住院、ICU收治、机械通气或插管。对于分类变量，使用Χ2检验进行差异性评估，而持续变量则使用Kruskal-Wallis秩和检验。建立多变量逻辑回归模型，相对于严重SARS-CoV-2感染发作和SARS-CoV-2感染死亡进行拟合。共诊断出352名肺癌患者感染COVID-19，其中61例患者（17.3％）于COVID-19确诊后4周内死亡，其他42例（11.9％）则经历了严重感染。与轻度或中度感染相比，死亡或严重感染的患者年龄较大，血红蛋白水平较低。与SARS-CoV-2感染死亡相关的因素包括年龄增长、免疫检查点抑制剂治疗和低血红蛋白水平。在本队列中，肺癌患者因COVID-19疾病死亡率低于文献中先前报道的死亡率。确定与严重或致命结果相关的风险因素有助于管理感染COVID-19疾病的肺癌患者。©2023年。此为美国政府工作，未受到美国版权保护;可能适用于外国版权保护。

Identifying lung cancer patients at an increased risk of getting SARS-CoV-2-related complications will facilitate tailored therapy to maximize the benefit of anti-cancer therapy, while decreasing the likelihood of COVID-19 complications. This analysis aimed to identify the characteristics of lung cancer patients that predict for increased risk of death or serious SARS-CoV-2 infection.This was a retrospective cohort study of patients with lung cancer diagnosed October 1, 2015, and December 1, 2020, and a diagnosis of COVID-19 between February 2, 2020, and December 1, 2020, within the Veterans Health Administration. Serious SARS-CoV-2 infection was defined as hospitalization, ICU admission, or mechanical ventilation or intubation within 2 weeks of COVID-19 diagnosis. For categorical variables, differences were assessed using Χ2 tests, while Kruskal-Wallis rank-sum test was used for continuous variables. Multivariable logistic regression models were fit relative to onset of serious SARS-CoV-2 infection and death from SARS-CoV-2 infection.COVID-19 infection was diagnosed in 352 lung cancer patients. Of these, 61 patients (17.3%) died within four weeks of diagnosis with COVID-19, and 42 others (11.9%) experienced a severe infection. Patients who had fatal or severe infection were older and had lower hemoglobin levels than those with mild or moderate infection. Factors associated with death from SARS-CoV-2 infection included increasing age, immune checkpoint inhibitor therapy and low hemoglobin level. The mortality of lung cancer patients from COVID-19 disease in the present cohort was less than previously reported in the literature. The identification of risk factors associated with severe or fatal outcomes informs management of patients with lung cancer who develop COVID-19 disease.© 2023. This is a U.S. Government work and not under copyright protection in the US; foreign copyright protection may apply.